EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Non-invasive testing and risk-stratification in patients with MASLD

Mirko Zoncapè, Antonio Liguori, Emmanuel A Tsochatzis

European Journal of Internal Medicine · 2024-04 · 122 · 11-19

DOI: 10.1016/j.ejim.2024.01.013 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Internal Medicine, 2024-04. Verfasst von Mirko Zoncapè und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK; UCL Institute for Liver and Digestive Health, University College London, UK; Liver Unit,…. Hauptthemen laut MEDLINE: Metabolic Diseases, Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 109 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development and validation of non-invasive fibrosis tests (NITs) has changed clinical practice in Hepatology over the last 15 years. Metabolic associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most prevalent liver disease in western countries, with up to a third of the unselected adult population affected. In this article, we review the use of NITs in the diagnosis and staging of MASLD. We discuss their use in the diagnosis of steatosis, steatohepatitis and fibrosis and critically evaluate recently published data. These NITs include a variety of approaches, such as serum markers like FIB-4, pro-C3 and ELF, imaging techniques like Fibroscan® and MRE, and combined scores like Agile 3+ and Agile 4, offering a range of options for healthcare providers. Furthermore, these non-invasive tests also serve as valuable prognostic tools, allowing for better risk assessment and improved patient management, particularly in predicting liver-related events and overall mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic DiseasesNon-alcoholic Fatty Liver DiseaseElasticity Imaging TechniquesAdultHumansHealth PersonnelLiver Cirrhosis

Stichwörter der Autor:innen

CirrhosisELFFIB4FibroscanNAFLD

Autor:innen und Institutionen

  • Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK; UCL Institute for Liver and Digestive Health, University College London, UK; Liver Unit, Department of Medicine, University of Verona and Azienda Ospedaliera…
  • Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK; UCL Institute for Liver and Digestive Health, University College London, UK; Medical and Surgical Sciences Department, Fondazione Policlinico Universitario A.…
  • Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK; UCL Institute for Liver and Digestive Health, University College London, UK. Electronic address: e.tsochatzis@ucl.ac.uk.

Zitieren

APA

Zoncapè, M., Liguori, A., & Tsochatzis, E. A. (2024). Non-invasive testing and risk-stratification in patients with MASLD. European Journal of Internal Medicine, 122, 11-19. https://doi.org/10.1016/j.ejim.2024.01.013

Vancouver

Zoncapè M, Liguori A, Tsochatzis EA. Non-invasive testing and risk-stratification in patients with MASLD. European Journal of Internal Medicine. 2024;122:11-19. doi:10.1016/j.ejim.2024.01.013

BibTeX
@article{Zoncap2024,
  author = {Zoncapè, Mirko and Liguori, Antonio and Tsochatzis, Emmanuel A},
  title = {Non-invasive testing and risk-stratification in patients with MASLD},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  volume = {122},
  pages = {11--19},
  doi = {10.1016/j.ejim.2024.01.013}
}
Kostenlos starten →